Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E - Deficient mice

Circulation

Volumn 103, Issue 21, 2001, Pages 2604-2609

  Kusunoki, Jun ^a,b   Hansoty, Dipal K ^a   Aragane, Katsumi ^b   Fallon, John T ^a   Badimon, Juan J ^a   Fisher, Edward A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b FUJIREBIO INC   (Japan)

Author keywords

Aorta; Cholesterol; Plaque

Indexed keywords

3 [N (2,2,5,5 TETRAMETHYL 1,3 DIOXANE 4 CARBONYL)AMINO]PROPIONIC ACID 2 (3 NEOPENTYL 3 NONYLUREIDO)CYCLOHEXYL ESTER; APOLIPOPROTEIN E; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA SINUS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FOAM CELL; HOMEOSTASIS; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

EID: 0035967492     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.21.2604     Document Type: Article

References (25)

1. Shattuck lecture: Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities
2. Acyl-coenzyme A:cholesterol acyltransferase
3. The pathogenesis of atherosclerosis: An update
4. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis
5. Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions: A biochemical, morphological, and morphometric evaluation
6. Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits: Evidence for a direct effect on the arterial wall
7. Novel effects of the acyl-coenzyme A:cholesterol acyltransferase inhibitor 58-035 on foam cell development in primary human monocyte-derived macrophages
8. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents
9. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1
10. Studies on acyl-CoA:cholesterol acyltransferase (ACAT) inhibitory effects and enzyme selectivity of F-1394, a pantotheic acid derivative
11. Hypocholesterolemic action and prevention of cholesterol absorption via the gut by F-1394, a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, in cholesterol diet-fed rats
12. Effects of F-1394, an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on ACAT activity in HepG2 cells and on hepatic secretion of lipids in Triton WR-1339-induced hyperlipidemic rats: Possible role of hepatic ACAT in very low density lipoprotein secretion
13. The lipid-laden foam cell: An elusive target for therapeutic intervention
14. Acyl-coenzyme A:cholesteryl acyltransferase 2
15. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice
16. Macrophages and atherosclerotic plaque stability
17. Postprandial hyperlipidemia in streptozotocin-induced diabetic rats is due to abnormal increase in intestinal acyl coenzyme A:cholesterol acyltransferase activity
18. Hypolipidemic action of F-1394, an acyl-CoA:cholesterol acyltransferase inhibitor, in high-fat diet fed beagle dogs
19. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits
20. Free cholesterol-induced cytotoxicity: A possible contributing factor to macrophage foam cell necrosis in advanced atherosclerosis
21. Crystallization of free cholesterol in model macrophage foam cells
22. Coronary plaque disruption
23. Macrophage infiltration in acute coronary syndromes: Implications for plaque rupture
24. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group